SUBJECTS : Biophysics Of Cancer | Metastasis | Histopathology | Carcinogenesi
LATEST MANUSCRIPTS IN npj Breast Cancer
- Sophia Leduc, Maxim De Schepper, François Richard, Marion Maetens, Anirudh Pabba, Kristien Borremans, Joris Jaekers, Emily Latacz, Gitte Zels, Ali Bohlok, Karen Van Baelen, Ha Linh Nguyen, Tatjana Geukens, Luc Dirix, Denis Larsimont, Sophie Vankerckhove, Eva Santos, Rui Caetano Oliveira, Kristòf Dede, Janina Kulka, Székely Borbala, Ferenc Salamon, Lilla Madaras, A Marcell Szasz, Valerio Lucidi, Yannick Meyer, Baki Topal, Cornelis Verhoef, Jennie Engstrand, Carlos Fernandez Moro, Marco Gerling, I. Histopathological growth patterns and tumor-infiltrating lymphocytes in breast cancer liver metastases. NPJ breast cancer. 2023, 9 (1): 100
Cited : 0Read More - Swaathi Jayaraman, Xinyan Wu, Krishna R Kalari, Xiaojia Tang, Mary J Kuffel, Elizabeth S Bruinsma, Shahrzad Jalali, Kevin L Peterson, Cristina Correia, Rachel A Kudgus, Scott H Kaufmann, Santosh Renuse, James N Ingle, Joel M Reid, Matthew M Ames, Alan P Fields, Matthew J Schellenberg, John R Hawse, Akhilesh Pandey, Matthew P Goetz. Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer. NPJ breast cancer. 2023, 9 (1): 101Cited : 0Read More
- Gina Kim, Burcu Karadal-Ferrena, Jiyue Qin, Ved P Sharma, Isabelle S Oktay, Yu Lin, Xianjun Ye, Saeed Asiry, Jessica M Pastoriza, Esther Cheng, Nurfiza Ladak, John S Condeelis, Esther Adler, Paula S Ginter, Timothy D'Alfonso, David Entenberg, Xiaonan Xue, Joseph A Sparano, Maja H Oktay. Racial disparity in tumor microenvironment and distant recurrence in residual breast cancer after neoadjuvant chemotherapy. NPJ breast cancer. 2023, 9 (1): 52Cited : 6Read More
- David B Page, Joanna Pucilowska, Brie Chun, Isaac Kim, Katherine Sanchez, Nicole Moxon, Staci Mellinger, Yaping Wu, Yoshinobu Koguchi, Valerie Conrad, William L Redmond, Maritza Martel, Zhaoyu Sun, Mary B Campbell, Alison Conlin, Anupama Acheson, Reva Basho, Philomena McAndrew, Mary El-Masry, Dorothy Park, Laura Bennetts, Robert S Seitz, Tyler J Nielsen, Kimberly McGregor, Venkatesh Rajamanickam, Brady Bernard, Walter J Urba, Heather L McArthur. A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer. NPJ breast cancer. 2023, 9 (1): 53Cited : 0Read More
- Yang Yang, Yingjian He, Zhaoqing Fan, Xue Chen, Yiqiang Liu, Chao Zhang, Hongchuan Jiang, Xin Wang, Xiang Wang, Fei Xie, Shu Wang, Bin Luo, Hua Kang, Tao Wang, Zefei Jiang, Peng Yuan, Binhe Xu, Ling Xu, Yinhua Liu, Jinfeng Li, Yuntao Xie, Tianfeng Wang, Tao Ouyang. Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial. NPJ breast cancer. 2023, 9 (1): 54Cited : 1Read More
- Alexandra Thomas, Jorge S Reis-Filho, Charles E Geyer, Hannah Y Wen. Rare subtypes of triple negative breast cancer: Current understanding and future directions. NPJ breast cancer. 2023, 9 (1): 55Cited : 4Read More
- Giuseppe Curigliano, Rebecca Dent, Antonio Llombart-Cussac, Mark Pegram, Lajos Pusztai, Nicholas Turner, Giuseppe Viale. Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer. NPJ breast cancer. 2023, 9 (1): 56Cited : 3Read More
- Jianli Ma, Yuwei Deng, Dawei Chen, Xiaomei Li, Zhiyong Yu, Haibo Wang, Lei Zhong, Yingjie Li, Chengqin Wang, Xiang Li, Jinming Yu, Qingyuan Zhang. Spatial immunophenotypes orchestrate prognosis in triple-negative breast cancer with Miller-Payne grade 4 following neoadjuvant chemotherapy. NPJ breast cancer. 2023, 9 (1): 57Cited : 0Read More
- Yan Ding, Fan Yang, Mengxue Han, Chunhui Li, Yanan Wang, Xin Xu, Min Zhao, Meng Zhao, Meng Yue, Huiyan Deng, Huichai Yang, Jianhua Yao, Yueping Liu. Multi-center study on predicting breast cancer lymph node status from core needle biopsy specimens using multi-modal and multi-instance deep learning. NPJ breast cancer. 2023, 9 (1): 58Cited : 4Read More
- Melinda Magna, Gyong Ha Hwang, Alec McIntosh, Katherine Drews-Elger, Masaru Takabatake, Adam Ikeda, Barbara J Mera, Taekyoung Kwak, Philip Miller, Marc E Lippman, Barry I Hudson. RAGE inhibitor TTP488 (Azeliragon) suppresses metastasis in triple-negative breast cancer. NPJ breast cancer. 2023, 9 (1): 59Cited : 1Read More
- Jing Yu, Edaise M da Silva, Hae-Sun La, Beth Z Clark, Jeffrey L Fine, Gloria J Carter, Tatiana M Villatoro, T Rinda Soong, Adrian V Lee, Steffi Oesterreich, Thais Basili, Juan Blanco-Heredia, Pier Selenica, Qiqi Ye, Arnaud Da Cruz Paula, Higinio Dopeso, Andrea Gazzo, Antonio Marra, Fresia Pareja, Jorge S Reis-Filho, Rohit Bhargava. Clinicopathologic and genomic features of lobular like invasive mammary carcinoma: is it a distinct entity? NPJ breast cancer. 2023, 9 (1): 60Cited : 1Read More
- Noortje Verschoor, Vanja de Weerd, Mai N Van, Jaco Kraan, Marcel Smid, Joan B Heijns, Jan C Drooger, Johanna M Zuetenhorst, Annemieke van der Padt-Pruijsten, Agnes Jager, Stefan Sleijfer, John W M Martens, Saskia M Wilting. Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival. NPJ breast cancer. 2023, 9 (1): 61Cited : 0Read More
- Yang Yang, Yingjian He, Zhaoqing Fan, Xue Chen, Yiqiang Liu, Chao Zhang, Hongchuan Jiang, Xin Wang, Xiang Wang, Fei Xie, Shu Wang, Bin Luo, Hua Kang, Tao Wang, Zefei Jiang, Peng Yuan, Binhe Xu, Ling Xu, Yinhua Liu, Jinfeng Li, Yuntao Xie, Tianfeng Wang, Tao Ouyang. Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial. NPJ breast cancer. 2023, 9 (1): 62Cited : 0Read More
- Sanne M Buijs, C Louwrens Braal, Stefan A J Buck, Noud F van Maanen, Lonneke M van der Meijden-Erkelens, Heleen A Kuijper-Tissot van Patot, Esther Oomen-de Hoop, Lotte Saes, Sophia J van den Boogerd, Liesbeth E M Struik, Quirine C van Rossum-Schornagel, Ron H J Mathijssen, Stijn L W Koolen, Agnes Jager. CBD-oil as a potential solution in case of severe tamoxifen-related side effects. NPJ breast cancer. 2023, 9 (1): 63Cited : 1Read More
- Lorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson, Susana Ros, Cath Eberlein, Jennifer I Moss, Jelena Urosevic, Larissa S Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffmann, Daniel Sutton, Stewart Jones, Richard J A Goodwin, Brandon S Willis, Claire Rooney, Elza C de Bruin, Simon T Barry. Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models. NPJ breast cancer. 2023, 9 (1): 64Cited : 2Read More
